Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Tree-based exploratory identification of predictive biomarkers in non-randomized data.

BMC medical research methodology·2026
Same author

Letermovir does not affect long-term polyclonal immune reconstitution after allogeneic hematopoietic stem cell transplantation with ATG-based GvHD prophylaxis.

Frontiers in immunology·2026
Same author

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

MRI Quality and Reader Experience in Organized Prostate Cancer Screening: Insights from the PROBASE Trial.

European urology oncology·2026
Same author

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Smart Screening in Prostate Cancer: What We Have Learned So Far from PROBASE.

European urology focus·2026
Same journal

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same journal

Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose Wisely.

European urology·2026
Same journal

Re: Dries Develtere, Riccardo Bertolo. Cumulative Genitourinary Toxicity After Prostate Radiotherapy: High-Level Long-Term Randomized Evidence. J Clin Oncol. Online ahead of print. http://dx.doi.org/10.1200/JCO-26-00436.

European urology·2026
Same journal

In Memory of Paul Mitrofanoff (1934-2025).

European urology·2026
Same journal

Re: McKay RR, Pal S, Xie W, et al. Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert Consensus on the Management of Renal Cell and Urinary Tract Cancers. CA Cancer J Clin 2026;76:e70052.

European urology·2026
Same journal

Re: Ultra-hypofractionated Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: 5-year Outcomes from a Pooled Analysis of the FASTRACK Trials.

European urology·2026
查看所有相关文章

相关实验视频

Updated: Jun 26, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

前列腺癌风险调整查 - - 通过PROBASE试验数据定义低风险组.

Agne Krilaviciute1, Rudolf Kaaks2, Petra Seibold1

  • 1Division of Personalized Early Detection of Prostate Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.

European urology
|May 15, 2024
PubMed
概括
此摘要是机器生成的。

45岁的男性,基线前列腺特异性抗原 (PSA) 水平低于1.5ng/ml,在未来五年内患前列腺癌 (PCa) 的风险非常低. 这些发现支持年轻男性PCa的风险调整查策略.

关键词:
低风险 低风险 低风险前列腺癌是什么意思 前列腺癌是什么意思前列腺特异性抗原前列腺特异性抗原查检查 查检查 查检查

更多相关视频

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.5K
Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
05:49

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

Published on: October 10, 2019

6.6K

相关实验视频

Last Updated: Jun 26, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.5K
Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
05:49

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

Published on: October 10, 2019

6.6K

科学领域:

  • 泌尿器科 泌尿器科 泌尿器科 泌尿器科
  • 在瘤学瘤学.
  • 查和诊断的使用

背景情况:

  • 前列腺癌风险调整查 (PCa) 旨在通过调整重复检测频率来最大限度地减少危害,特别是在低风险人群中.
  • 目前对低风险的定义主要基于涉及55-60岁男性进行查的研究.

研究的目的:

  • 为了确定45岁时患前列腺癌 (PCa) 风险较低的男性.

主要方法:

  • 这项研究使用了德国的一项基于人群的风险调整PCa选试验 (PROBASE).
  • 基线前列腺特异性抗原 (PSA) 测量从45岁开始进行.
  • 在5年内PCa的发生率与基线PSA水平 (<1.5 ng/ml与1.5-3.0 ng/ml) 相比进行了评估.

主要成果:

  • 在45岁时测试的23301名男性中,0.79%的PSA≥3 ng/ml.
  • 基线 PSA <1.5 ng/ml (89%的参与者) 的男性在5年内随后的阳性 PSA 测试率仅为0.45%.
  • 基线PSA为1.5-3.0 ng/ml的男性显示,在4年内超过3 ng/ml的比率 (13%) 显著更高.
  • PCa发生率与基线PSA水平增加,从每1000人年0.13到8.0不等.

结论:

  • 在45岁时PSA基线<1.5ng/ml的男性在随后的5年中显示PCa的风险非常低.
  • 这些结果表明,在45岁时PSA基线<1.5 ng/ml的男性可能不需要在5年内重新进行PSA测试.
  • 这些发现支持在年轻男性中应用风险调整的前列腺癌查方案.